Brokers Issue Forecasts for Cingulate FY2025 Earnings

Cingulate Inc. (NASDAQ:CING) – HC Wainwright issued their FY2025 earnings per share estimates for Cingulate in a report released on Thursday, January 30th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings of ($2.97) per share for the year. HC Wainwright currently has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Cingulate’s current full-year earnings is ($11.69) per share.

Cingulate (NASDAQ:CING) last released its earnings results on Thursday, November 7th. The company reported ($1.83) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.22) by $0.39.

Other equities research analysts have also recently issued research reports about the company. Roth Capital raised Cingulate to a “strong-buy” rating in a report on Friday, January 10th. Roth Mkm initiated coverage on shares of Cingulate in a report on Friday, January 10th. They issued a “buy” rating and a $12.00 price objective for the company. Finally, Maxim Group raised shares of Cingulate from a “hold” rating to a “buy” rating in a research note on Wednesday, November 20th.

Cingulate Price Performance

Shares of NASDAQ CING opened at $4.55 on Friday. Cingulate has a 12-month low of $1.80 and a 12-month high of $58.32. The company has a 50-day moving average of $4.59 and a 200 day moving average of $4.53.

Institutional Trading of Cingulate

A hedge fund recently raised its stake in Cingulate stock. AlphaMark Advisors LLC raised its position in Cingulate Inc. (NASDAQ:CING) by 50,000.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,010 shares of the company’s stock after purchasing an additional 5,000 shares during the quarter. AlphaMark Advisors LLC owned 0.16% of Cingulate worth $25,000 as of its most recent SEC filing. Institutional investors and hedge funds own 41.31% of the company’s stock.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.